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1. Introduction 
The rapid and sensitive methods for separation and quantification of bioactive compounds 
are essential for quality control of the traditional Chinese medicine (TCM) and crude 
extracts. However, it seems that the current systems in use are not necessarily optimum 
approaches. For example, various methods for separation and quantification of glycyrrhizin 
(GC), the main active constituent in licorice (Glycyrrhiza spp.), have been used such as gas 
chromatography, high performance liquid chromatography (HPLC), and micellar trokinetic 
chromatography (Ong, 2002; Lay et al., 2004; Tan et al., 2002). Commercial purification of 
GC typically progressed through several steps, including crystallization, column 
chromatography, and liquid partitioning. However, these methods are far from satisfactory 
analytical purpose in terms of high sensitivity, reproducibility, large amounts of extraction 
solvents and time-consuming factors. 
Owning to the rapid development of the molecular biosciences and their biotechnological 
applications, immunoassays using monoclonal antibodies (MAbs) against target molecules 
such as proteins, drugs and low-molecular-weight bioactive compounds have become one 
of the important tools by taking advantage of their specificity. Immunoassay by MAbs is 
used in a wide variety of analysis such as receptor binding assays, enzyme assays, and 
quantitative and qualitative analytical techniques both in vivo and in vitro studies. 
Immunoaffinity purification is a highly specific technique that has the potential to be used 
for the one-step isolation of a target molecule from many complex mixtures like a cellular 
lysate. Immunoaffinity columns are conjugated with MAbs and work by specifically binding 
and removing the target molecules. Several immunoaffinity columns like a protein G 
affinity column for MAbs expressed by hybridoma and a metal chelate affinity column for 
single chain variable fragment (Fv) proteins expressed by E. coli have been commonly used 
for the purification of peptides and proteins. Application of an immunoaffinity column may 
decrease the amount of solvent used and the number of purification steps, shorten analysis 
time, and simplify sample analysis compared to traditional cleanup techniques. Although 
immunoaffinity purification against higher molecule analyte such as peptides and proteins 
are widely used in the research and commercial ways, there are too few cases of 
immunoaffinity purification targeting a small molecule compound. Fortunately, in our 
ongoing studies of naturally occurring bioactive compounds we have prepared many kinds 
of MAbs against terpenoids (Sakata et al., 1994; Xuan et al., 1999; Lu et al., 2003), alkaloids 
(Shoyama et al., 1996; Kim et al. 2004), plant saponins (Tanaka et al., 1999; Fukuda et al., 
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2000b; Zhu et al., 2004; Shan et al., 2001; Ishiyama et al., 1996), and phenolics (Morinaga et 
al., 2000; Morinaga et al., 2001; Tanaka et al., 1996; Loungratana et al., 2004), and set up the 
enzyme-linked immunosorbent assay (ELISA) for quality control of the TCM. Furthermore, 
we have been establishing several affinity column with MAb against a kind of terpenoid, 
forskolin (Yanagihara et al., 1996), solasodine glycosides (Putalun et al., 1999), ginsenosides 
Rb1 (Fukuda et al., 2000c), and GC (Xu et al., 2007).  
In this chapter, we introduce the new strategy to isolate and concentrate the target bioactive 
compounds from the crude extract by immunoaffinity column using individual MAb. We 
succeeded one-step purification of target compounds by MAb-conjugated immunoaffinity 
column, which leads to the knock-out (KO) extract which contains all components except an 
antigen molecule. The KO extract will be useful for the pharmacological investigation to 
reveal real effects of bioactive compound in the crude extract and the interaction between 
the target compound and other compounds.  
2. One step concentration by immunoaffinity column conjugated with anti-
ginsenoside Rb1 MAb 
Ginseng, the crude drug of Panax ginseng root, has been used as a therapeutic herbal 
medicine in Asian countries and one of the most important components in TCM for 
thousands of years. The pharmacological and biological activities of ginseng have been 
reported to have anti-aging, anti-cancer, anti-inflammation, anti-diabetics, anti-stress, 
maintenance of homeostasis, and to affect on central nervous system and immune function 
(Gillis et al., 1997). Ginsenosides are believed to account for the pharmacological activities of 
ginseng. It is well known that the concentrations of ginsenosides vary in the ginseng root or 
the root extracts depending on the method of extraction, subsequent treatment, or even the 
season of its collection (Kitagawa et al., 1989; Tanaka et al., 1989). Recently, the individual 
ginsenosides in ginseng are purified by preparative HPLC. However, the repeated 
purification is required and may result in the decrease of the final yield. Therefore, the 
developed approaches for quality control are required in the field of TCM. 
Ginsenosides are normally fractioned into two groups based on the types of aglycone, 
namely the protopanaxadiol group and the protopanaxatriol group. Within more than 30 
different ginsenosides, ginsenoside Rb1 (G-Rb1), one of the protopanaxadiols, is considered 
the most important active factor (Washida & Kitanaka, 2003). G-Rb1 has various biological 
activities, including facilitating acquisition and retrieval of memory (Mook-Jung et al., 2001), 
scavenging free radicals (Lim et al., 1997), inhibition of calcium over-influx into neurons 
(Liu & Zhang, 1995), and preserving the structural integrity of the neurons (Jiang & Qian, 
1995). 
To control the quality of ginseng, the preparation of anti-G-Rb1 MAb, set up of ELISA, and a 
new immunostaining method named Eastern blotting were reported (Tanaka et al., 1999; 
Fukuda et al., 2000a). Herein, we describe an immunoaffinity column procedure for G-Rb1 
and its application in single step isolation from crude extract of ginseng root. 
2.1 Preparation of immunoaffinity column against G-Rb1 
Purified anti-G-Rb1 MAb (10 mg) in diluted Affi-Gel Hz coupling buffer was dialyzed 
against the coupling buffer two times. The dialyzed anti-G-Rb1 MAb was treated by NaIO4 
to give dialdehyde group in sugar moiety which was coupled to Affi-Gel Hz hydrazide gel. 
The immunoaffinity gel was packed into plastic mini-column (Figure 1). 
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Fig. 1. Scheme of preparation of anti-G-Rb1 immunoaffinity column 
 
 
Fig. 2. TLC (A) and Eastern blotting (B) profiles for a standardized ginsenosides mixture. 
The TLC plate and Eastern blotting membrane were stained by H2SO4 and incubated with 
anti-G-Rb1 MAb, respectively 
2.2 Optimal buffer systems for separation of G-Rb1 
Firstly, to examine the optimal conditions of adsorption and elution, 400 μg of G-Rb1 was 
dissolved in phosphate buffer (PB) and loaded on anti-G-Rb1 affinity column. After washing 
with washing buffer (20 mM PB containing 0.5 M NaCl), various buffer solutions for elution 
were loaded on the column, and then the recovery efficiency was determined by ELISA. The 
G-Rb1 concentration was slightly increased by eluting with a 20 mM PB containing 0.5 M 
KSCN and 10 % MeOH. When the 20 mM PB was changed to 100 mM AcOH buffer (pH 4), 
the elution ability reached the optimal level. Since 20 % MeOH could elute G-Rb1 efficiently, 
higher MeOH concentration of over 20 % was ineffective. Thus, 100 mM AcOH buffer 
containing 0.5 M KSCN and 20 % MeOH could be used as an elution buffer in subsequent 
immunoaffinity chromatography. 
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2.3 One step purification of G-Rb1 from a standardized ginsenosides mixture by anti-
G-Rb1 immunoaffinity column 
To confirm the concentration of G-Rb1 by anti-G-Rb1 affinity column, a ginsenoside mixture 
containing 100 μg each of ginsenoside Rg1, Re, Rd, Rc, and chikusetsusaponin IV (chik IV; 
an oleanane-type saponin) were loaded on the column. Figure 2 shows the TLC and Eastern 
blotting profiles of ginsenosides and chik IV in washing and elution buffers flowed from the 
affinity column. When the column was washed with washing buffer (20 mM PB containing 
0.5 M NaCl), ginsenoside Rg1, Re, Rd, Rc, chik IV, and overcharged G-Rb1 were detected. 
After these compounds were completely washed out by washing buffer, the G-Rb1 bound to 
anti-G-Rb1 MAb was eluted by elution buffer (100 mM AcOH buffer containing 0.5 M 
KSCN and 20 % MeOH). 
2.4 One step purification of G-Rb1 from crude extract of P. ginseng roots by anti-G-
Rb1 immunoaffinity column 
A crude extract of P. ginseng roots (3.8 mg) was loaded onto anti-G-Rb1 immunoaffinity 
column. After washing with washing buffer (fractions 1-20), the column was eluted with 
elution buffer (fractions 21-40). As shown in Figure 3, the G-Rb1 concentration in the 
collected fractions was determined by ELISA. After loading of crude extract, overcharged G-
Rb1 was detected in washing buffer of fractions 1-8. G-Rc, Rd, Re, and Rg1 were also 
detected in these fractions by Eastern blotting procedure (data not shown). A sharp peak of 
G-Rb1 was observed around fractions 21-24 of elution buffer. However, these eluted 
fractions were investigated by Eastern blotting, and the purified G-Rb1 in these fractions 
was still contaminated by a small amount of malonyl-G-Rb1, which having almost the same 
cross-reactivity with G-Rb1 (data not shown). Therefore, the mixture was treated with a 
mild alkaline solution (0.1 % KOH in MeOH) at room temperature to give pure G-Rb1. 
Overcharged G-Rb1 in washing solution (fractions 1-8) was repeatedly loaded and finally 
isolated in pure form. The anti-G-Rb1 MAb was stable during all procedures, and the 
immunoaffinity column showed almost no decrease in capacity (20 μg of G-Rb1/ml gel) 
after repeated use more than 10 times under same conditions. 
After washing the column, each fraction of washing and elution were deionized and the 
solvent was lyophilized. Figure 4 demonstrated that TLC profile of the purification steps. 
Lane 1 and 2 were spotted the standard of ginsenosides (G-Rd, G-Rc, G-Rb1, G-Rg1, and G- 
Re). Lane A, B, and C were the crude extract, the washing fraction, and the eluted fraction, 
respectively. In the crude extract (lane A), all spots of ginsenosides were clearly detected. 
Interestingly, the washing fraction (lane B) contained all of the ginsenosides in the crude 
extract except G-Rb1. Furthermore, the spot of G-Rb1 was detected in the eluted fractions 
(lane C). These data strongly indicated that G-Rb1 molecule in the ginseng extract can be 
eliminated by an anti-G-Rb1 immunoaffinity column and the washing fractions was knock-
out only by the antigen molecule, G-Rb1. Thus, we named the washing fractions a knock-out 
(KO) extract (Wang & Shoyama, 2006; Tanaka et al., 2007). 
Since we succeeded the preparation of MAbs having a wide cross-reactivity like anti-
solamargine MAb (Ishiyama et al., 1996), anti-saikosaponin a (Zhu et al., 2004) and 
ginsenoside-Re (Morinaga et al., 2006), the related total saponins can be removed by an 
immunoaffinity column conjugated with MAb in the case of solasodine glycosides, as 
reported previously (Putalun et al., 1999). The newly developed KO extract may be useful 
for the determination of real pharmacologically active principle in the TCMs. 
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Fig. 3. Elution profile of P. ginseng crude extract by anti-G-Rb1 immunoaffinity column. G-Rb1 
of each fraction was monitoring by ELISA using anti-G-Rb1 MAb. The volume of individual 
fraction was 2 mL. *Inhibition = (A0-A)/A0 ;A0 is the absorbance in the absence of the test 
compounds. A is the absence in the presence the test compounds (Fukuda et al., 2000c) 
 
 
Fig. 4. Scheme of the preparation of G-Rb1 KO extract from P. ginseng crude extract using 
anti-G-Rb1 immunoaffinity column (A) and TLC profile of the separated fractions by the 
column (B). Lane 1 and 2 indicate the standard of ginsenosides (G-Rd, G-Rc, G-Rb1, G-Rg1, 
and G-Re). Lane A, B, and C were the crude extract, the washing fraction, and the eluted 
fraction, respectively (Fukuda et al., 2000c) 
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2.5 Isolation and determination of ginsenosides by anti-G-Rb1 immunoaffinity column 
The anti-G-Rb1 immunoaffinity column could separate G-Rb1 from the crude extract of P. 
ginseng. In this case, malonyl-G-Rb1 was also eluted by elution buffer together with G-Rb1, 
because that this anti-G-Rb1 MAb has the cross-reactivity with malonyl-G-Rb1. Therefore, 
the pre-treatment of P. ginseng extract with a mild alkaline solution was needed to convert 
into pure G-Rb1. 
Table 1 indicates the G-Rb1 concentration in several ginseng roots determined by ELISA by 
anti-G-Rb1 MAb and HPLC after pre-treatment under mildly alkaline condition. The fibrous 
ginseng made from the active growing part of P. ginseng showed the highest G-Rb1 
concentration. White ginseng was prepared from P. ginseng simply by drying. The 
concentration of G-Rb1 was higher than that red ginseng, but lower compared with the 
other samples except Japanese ginseng. Red ginseng is prepared by steaming and drying the 
root of P. ginseng. Eastern blotting analysis indicated that the red ginseng contained few of 
malonyl-G-Rb1, which is a distinctive feature of it (data not shown). These data suggests 
that the steaming step for the preparation of red ginseng decreases the concentration of G-
Rb1 by conversion into C-20 hydroxy free ginsenosides (Kitagawa et al., 1983). Among these 
tested samples, the lowest concentration of G-Rb1 was detected in Japanese ginseng (P. 
japonicus). Interestingly, the G-Rb1 concentration of P. japonicus was not correlated between 
ELISA and HPLC.  
 
G-Rb1 content (μg/mg dry wt.) 
Sample 
ELISA HPLc 
White ginseng (P. ginseng) 5.49 ± 0.75 4.96 ± 0.05 
Red ginseng 3.57 ± 0.62 3.93 ± 0.34 
Fibrous ginseng 64.44 ± 3.64 69.75 ± 1.45 
San-chi ginseng (P. notoginseng) 47.08 ± 3.34 42.39 ± 1.39 
American ginseng (P. quinquefolium) 48.51 ± 1.79 47.96 ± 1.04 
Japanese ginseng (P. japonicus) 1.37 ± 0.34 0.63 ± 0.06 
Table 1. G-Rb1 content of various ginseng samples after pre-treatment with mildly alkaline 
condition 
P. japonicus is distributed in Japan and China and it is morphologically different from the 
other Panax species. The phytochemical profiles indicated that no G-Rbl was detected in P. 
japonicus, and isolated oleanane-type saponins named as chikusetsusaponins and elucidated 
their structures (Yahara et al., 1977). Morita et al. examined the varieties of saponins in P. 
japonicus by chemical analysis (Morita et al., 1985). From these results, the concentration of 
G-Rb1 might be trace level in P. japonicus. However, as shown in Table 1, G-Rb1 was 
detected by ELISA in P. japonicus crude extract pre-treated with a mild alkaline solution and 
found higher concentrations compared with HPLC and previous reports (Morita et al., 
1985). This data suggest that anti-G-Rb1 MAb using ELISA has the cross-reactivity with 
some unknown compounds. 
To investigate the unknown compounds bound to anti-G-Rb1 MAb, the crude extract of P. 
japonicus was concentrated by immunoaffinity column using anti-G-Rb1 MAb. The crude 
root extract was loaded on the column and washed with the washing buffer, followed by the 
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elution buffer as indicated in Figure 4. Figure 5 shows the H2SO4 staining (A) and the Eastern 
blotting (B) profiles of the two fractions separated by the immunoaffinity column. Fractions 
eluted with the washing buffer (lane A-D) showed many spots, including ginsenosides and 
chikusetsusaponins, similar to the original extract of P. japonicus. After washing, the column 
was eluted by elution buffer (lane E), and then one spot was detected. Interestingly, Eastern 
blotting indicated two different spots on lane A (the washing fraction containing the 
overcharged compounds) and one spot on each lane B and E. These compounds bound with 
anti-G-Rb1 MAb have a dammarane saponin having protopanaxadiol as a framework. 
Compound 1 detected in the washing fraction had an Rf value close to that of G-Rd, indicating 
that this compound has three sugar moieties in a molecule. Considering the previous study 
compound 1 is chikusetsusaponin III (chik III) has three sugars, one xylose and two glcoses 
in a molecule (Morita et al., 1985) (Figure 6). Finally, this compound was identified as chik 
III in a direct comparison with authentic sample. These data indicated that the specificity of 
anti-G-Rb1 MAb against chik III of immunoaffinity column is higher than that of Eastern 
blotting because the antigen (chik III) conjugated with carrier protein via sugar chain to fix 
on the membrane in case of Eastern blotting, so the structure of chik III was changed.  
Another unknown spot, compound 2 appeared in fraction A of the overcharged washing 
fraction and fraction E of the eluted fraction. G-Rb1 was not detected by Eastern blotting 
although it was determined by TLC as indicated in Figure 5. It can be suggested that 
compound 2 has a similar molecular structure and cross-reactivity with G-Rb1, and seems to 
be related ginseng saponin having protopanaxadiol as an aglycone. Moreover, compound 2 
is more polar than G-Rb1, indicating that it possess 5 sugar moiety compared with G-Rb1. 
Although compound 2 was treated with a mild alkaline solution, no change occurred. From 
these evidences compound 2 might be chikusetsusaponin III-20-O-gentiobiose 
(chikusetsusaponin VI; Figure 6) having 5 sugars in a molecule in good agreement with the 
Rf value previously reported (Kohda et al., 1991) and we confirmed that compound 2 is chik 
VI by the direct comparison with authentic sample (Fukuda et al., 2000a). 
 
 
Fig. 5. TLC (A) and Eastern blotting (B) profiles of the separated fractions from P. japonicus 
crude extract by the anti-G-Rb1 immunoaffinity column. Lane 1 indicates the standard of 
ginsenosides (G-Rd, G-Rc, G-Rb1, G-Rg1, and G-Re). Lane A-D and Lane E were the 
washing fractions and the eluted fraction, respectively (Fukuda et al., 2000a) 
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Fig. 6. Chemical structures of G-Rb1 and chikusetsusaponins purified from P. japonicus by 
the anti-G-Rb1 immunoaffinity column 
Taken together, P. japonicus root contains no G-Rb1 as previously reported (Yahara et al., 
1977). However, the immunoaffinity column conjugated with anti-G-Rb1 MAb could 
concentrate some unknown structurally resemble compounds having cross-reactivity 
against anti-G-Rb1 MAb. Thus, this purification system will be applied to survey new 
compounds related to target compound of MAb. In a previous report, a immunoaffinity 
purification against solasodine glycosides purified all solasodine glycosides by one-step 
purification. In this case, all solasodine glycoside have almost same cross-reactivity against 
anti-solamargine MAb (Ishiyama et al., 1996). 
3. Preparation of GC-knock out extract and its application for in vitro assay 
Licorice (Glycyrrhiza spp.) is another important crude drug used in over 70 % of TCMs. It 
mainly consists of dried roots and stolons of Glycyrrhizae uralensis, G. inflate and G. glabra. 
Licorice is prescribed with other herbal medicines as an anti-tussive, an expectorant, and an 
anti-inflammatory agent (Asl & Hosseinzadeh, 2008). The pharmacological properties of 
licorice depend upon GC, which is considered to be its main active constituent (Figure 7). It 
has been reported that GC exhibits numerous pharmacological effects such as anti-
inflammation, anti-ulcer, anti-cancer, and anti-viral activities (Asl et al., 2008; Wang & 
Nixon, 2001; Doll & Hill, 1962; Pompei et al., 1979). Clinically, GC has been used to treat 
patients with chronic hepatitis (Schalm et al., 1999; Coon & Ernst, 2004). Moreover, GC is 
used in food additives and cosmetics as a well-known natural sweetener (Kim & Kinghorn, 
2002). The quality standardization of licorice is usually based on its GC content. Recently, 
the utilization volume of licorice is rapidly increasing, while the availability of wild licorice 
has declined to curb overexploitation of the natural resources (Yamamoto et al., 2003; 
Hayashi et al., 2003). For the promotion of effective cultivation of licorice as an additional 
and stable herbal resource, the rapid and easy measurement methods of the GC content are 
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required. Previously, we established anti-GC MAb and a fast and sensitive assay system 
using the MAb for the screening of GC concentration in large numbers of samples (Tanaka 
& Shoyama, 1998; Shan et al., 2001), the sensitive detection of GC by surface plasmon 
resonance-based immunosensor (Sakai et al., 2004), and the rapid detection by 
immunochromatographic assay (Putalun et al., 2005). The purpose of our recent studies is to 
purify and quantify GC from licorice crude extract by anti-GC-MAB immunoaffinity 
chromatography to expand the possibilities for pharmacological research and other 
applications. 
 
 
Fig. 7. Chemical structure of GC 
3.1 Preparation of GC-KO extract by anti-GC immunoaffinity column 
Previously, we have reported the preparation of anti-GC MAb, and its cross-reactivity of the 
anti-GC MAb against glycyrrhetic acid-3-O-glucuronide and glycyrrhetic acid were 0.585 % 
and 1.865 %, respectively, compared with GC (Tanaka & Shoyama, 1998; Shan et al., 2001). 
The other related compounds such as deoxycholic acid, ursolic acid, and oleanolic acid, 
were all less than 0.005 %. The purified 60 mg of the anti-GC MAb was coupled to 25 ml of 
an Affi-Gel Hz gel and used to prepare the immunoaffinity column. 
Twelve milligrams of licorice crude extract containing 1275.0 μg of GC was dissolved in 
loading buffer (5 % MeOH), and then applied on the anti-GC-MAb immunoaffinity column. 
The column was washed with washing buffer (5 % MeOH) and then eluted with elution 
buffer (20 mM phosphate buffer containing 30 % MeOH). After separation, each fraction 
was deionized and the solvent was lyophilized. Table 2 indicates the GC concentration of 
washing and eluted fractions determined by ELISA. The washing and eluted fractions 
contain and 3.50 μg and 1269.26 μg of GC, respectively. These data indicate that the anti-GC 
column could eliminate 99.55 % of the loading GC. Thus, we named this washing fraction 
“GC-knock out (GC-KO) extract”. The capacity of the anti-GC immunoaffinity column was 
effective to capture GC compared with the immunoaffinity columns for forskolin and 
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solasodine glycosides (Yanagihara et al., 1996; Putalun et al., 1999). This result may also 
infer that when the GC concentration is trace level or cannot be analyzed by even ELISA, 
this anti-GC immunoaffinity column can concentrate GC to the detectable level. The 
combination of the established anti-GC-MAb immunoaffinity column and ELISA provided a 
reliable and very high sensitive analysis for GC in different extracts of various medicinal 
herbs or other drugs. 
 
 
Table 2. GC content of the loading licorice extract and the separated fractions by anti-GC 
immunoaffinity column 
To investigate the profiles of GC-KO extract, we performed the TLC analysis and Eastern 
blotting. As shown in Figure 8A, several spots of GC and other compounds were detected in 
licorice extract (lane 2). However, although all other spots were clearly detected, the spot of 
GC was completely disappeared in GC-KO extract (lane 3). Furthermore, Eastern blotting by 
anti-GC MAb indicated that GC was detected in licorice extract (lane 2), but the spot of GC 
was disappeared in GC-KO extract (lane 3) (Figure 8B). Taken together, these data suggest 
that GC was specifically eliminated from licorice extract by anti-GC MAb immunoaffinity 
column. 
 
 
Fig. 8. TLC profiles (A) and Eastern blotting by anti-GC MAb (B) of licorice extract and GC-KO 
extract. Lane 1; GC strandard, Lane 2; licorice extract, Lane 3; GC-KO extract 
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3.2 The application of GC-KO extract prepared by anti-GC immunoaffinity column to in 
vitro assay 
Inflammation leads to the up-regulation of a series of enzymes and signaling mediators in 
the affected tissue and cells. Nitric oxide (NO) is a highly reactive free radical involved in 
multiple physiological functions, such as vasodilatation, neurotransmission and inflammation 
(Moncada et al., 1991). During inflammatory process, a large amount of NO is produced by 
inducible nitric oxide synthase (iNOS) by inflammatory cytokines and/or bacterial 
lipopolysaccharide (LPS) in various cell types including macrophages (Nathan & Xie, 1994). 
Overproduced NO synthesized by iNOS triggers the pathogenesis of septic shock and organ 
destruction in certain inflammatory and autoimmune diseases (Naseem et al., 2005; Guzik et 
al., 2003; Abramson et al., 2001). Therefore, inhibiting NO production by blocking iNOS 
expression may be useful strategy to treat a variety of inflammatory diseases. 
Initially, we examined whether licorice crude extract suppress NO release in LPS-treated 
mouse RAW264 macrophages. LPS evoked a dramatic increase of NO production, and this 
induction was blocked by treatment of licorice extract dose dependently (12.5-100 μg/mL) 
(data not shown). Next, we performed Western blot analyses and RT-PCR to investigate the 
effect of licorice extract on iNOS protein and mRNA expressions. LPS markedly up-regulated 
iNOS protein and mRNA level, and pretreatment of licorice extract reduced these up-
regulations in the same concentration range as was used for NO production (data not shown).  
At 100 μg/mL of licorice extract, iNOS protein and mRNA were completely suppressed.  
ELISA by using anti-GC MAb demonstrated that 100 μg of licorice extract contains 10.6 ± 
0.618 μg of GC. To examine whether GC alone can reduce NO production and iNOS 
expression, we pretreated the cells with GC around 10.6 μg/ml before exposure to LPS. 
However, GC did not exert any significant influence on LPS-induced NO production and 
iNOS protein expression (data not shown). 
 
 
Fig. 9. Effect of licorice extract, GC-KO extract, and the co-treatment of GC-KO extract and 
GC on NO production (A) and iNOS protein expression (B) in LPS-treated RAW264 cells. 
Each bar represents the means ± S.D. from four separate experiments. *P<0.05, **P<0.01, 
*P<0.001 compared with LPS alone 
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To further elucidate the effect of GC on NO inhibition by licorice extract, we used GC-KO 
extract prepared by anti-GC immunoaffinity column. According to data of ELISA, 100 μg of 
licorice extract contains 10.6 μg of GC and 89.4 μg of the other compounds. Thus, the cells 
were treated with licorice extract (100 μg/mL), GC-KO extract (89.4 μg/mL), or combination 
of GC-KO extract (89.4 μg/mL) and GC (10.6 μg/mL). As shown in Figure 9A, although 
treatment of licorice extract lead to an inhibition of NO production as compared to LPS 
treatment [inhibition ratio (IR) = 57.7%], the inhibitory effect of GC-KO extract was 
decreased compared with licorice extract (IR = 17.8 %). Interestingly, the combination of GC-
KO extract and GC significantly improved the inhibitory ability (IR = 33.5 %). Furthermore, 
we performed Western blotting to determine whether the combinational effect of GC-KO 
extract and GC was related to iNOS expression (Figure 9B). Inhibitory activity of iNOS 
expression by licorice extract was reduced in treatment of GC-KO extract. The addition of 
GC to GC-KO extract improved the inhibition. These data suggest that GC alone cannot 
suppress iNOS expression, but combinational inhibition of iNOS expression may occur 
when GC coexists with the other constituents contained in licorice extract.  
In conclusion, this study demonstrate that KO extract prepared by anti-natural compound 
specific MAb-conjugated immunoaffinity column is a useful approach for determination of 
potential function of natural compound on in vitro and in vivo assays. 
4. Conclusion 
We describe the new strategy of one-step purification of target compounds from crude 
extract by anti-natural compound MAb-conjugated immunoaffinity column. The 
combination of the immunoaffinity column and ELISA by using MAb provided a reliable 
and high sensitivity analysis for target compound in various crude extracts and TCMs. 
Furthermore, by the use of the cross-reactivity of MAb, the affinity column can identify new 
unknown compounds related to target compound of MAb and determine their structures. 
Finally, we demonstrate that KO extract, which contains all components of crude extract 
except an antigen molecule, may be useful approach to determine the potential function of 
one principal compound on the crude extract or TCM by in vitro and in vivo assays.  
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